Total Payments
$419.54
2023 Payments
$29.64
Companies
6
Transactions
39
Medicare Patients
14,521
Medicare Billing
$814,052
Payment Breakdown by Category
Food & Beverage$419.54 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $419.54 | 39 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $221.92 | 17 | $0 (2018) |
| Allergan Inc. | $110.96 | 17 | $0 (2017) |
| AbbVie Inc. | $29.64 | 1 | $0 (2023) |
| Novo Nordisk Inc | $27.96 | 2 | $0 (2018) |
| Vanda Pharmaceuticals Inc. | $14.71 | 1 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $14.35 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $29.64 | 1 | AbbVie Inc. ($29.64) |
| 2020 | $14.71 | 1 | Vanda Pharmaceuticals Inc. ($14.71) |
| 2018 | $52.47 | 4 | Supernus Pharmaceuticals, Inc. ($36.75) |
| 2017 | $322.72 | 33 | Supernus Pharmaceuticals, Inc. ($185.17) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/12/2023 | AbbVie Inc. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.64 | General |
| Category: NEUROSCIENCE | ||||||
| 02/05/2020 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/03/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.18 | General |
| Category: AED | ||||||
| 10/23/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.99 | General |
| Category: AED | ||||||
| 07/24/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $13.58 | General |
| Category: AED | ||||||
| 04/24/2018 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Diabetes | ||||||
| 12/12/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $12.70 | General |
| Category: AED | ||||||
| 12/06/2017 | Allergan Inc. | LINZESS (Drug), VIBERZI | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/16/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $3.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.42 | General |
| Category: AED | ||||||
| 10/12/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $4.10 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/06/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.34 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $21.15 | General |
| Category: AED | ||||||
| 09/07/2017 | Allergan Inc. | VIIBRYD (Drug) | Food and Beverage | In-kind items and services | $4.59 | General |
| Category: NEUROSCIENCE | ||||||
| 08/31/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $2.24 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/27/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $4.70 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/20/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $9.03 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/22/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/15/2017 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $8.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/06/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $16.88 | General |
| Category: AED | ||||||
| 06/06/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $3.71 | General |
| Category: AED | ||||||
| 05/26/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $9.84 | General |
| Category: AED | ||||||
| 05/26/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.16 | General |
| Category: AED | ||||||
| 05/26/2017 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $4.94 | General |
| Category: AED | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 3,579 | 7,423 | $670,212 | $249,941 |
| 2022 | 25 | 3,436 | 6,284 | $507,301 | $190,709 |
| 2021 | 32 | 3,745 | 6,746 | $539,693 | $203,008 |
| 2020 | 31 | 3,761 | 6,679 | $480,939 | $170,394 |
Total Patients
14,521
Total Services
27,132
Medicare Billing
$814,052
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 426 | 817 | $198,099 | $66,668 | 33.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 268 | 268 | $80,132 | $32,136 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 260 | 515 | $88,292 | $30,293 | 34.3% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 138 | 491 | $70,704 | $22,435 | 31.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 45 | 45 | $17,640 | $12,394 | 70.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 75 | 324 | $39,556 | $11,464 | 29.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 463 | 1,385 | $11,714 | $11,183 | 95.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 62 | 70 | $23,758 | $8,297 | 34.9% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 59 | 59 | $17,228 | $8,294 | 48.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 454 | 1,093 | $21,860 | $8,290 | 37.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 114 | 114 | $10,374 | $8,200 | 79.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 122 | 122 | $7,076 | $3,486 | 49.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 54 | 89 | $9,968 | $3,148 | 31.6% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 20 | 20 | $7,640 | $3,067 | 40.1% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 27 | 336 | $9,744 | $2,532 | 26.0% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 64 | 64 | $5,312 | $2,437 | 45.9% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 63 | 63 | $5,229 | $2,361 | 45.2% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 32 | 38 | $9,500 | $1,953 | 20.6% |
| 85610 | Blood test, clotting time | Office | 2023 | 29 | 397 | $4,367 | $1,667 | 38.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 36 | 40 | $4,360 | $1,401 | 32.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 44 | 44 | $2,378 | $1,257 | 52.9% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 251 | 389 | $3,112 | $1,210 | 38.9% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 77 | 77 | $3,311 | $1,010 | 30.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 87 | 98 | $4,410 | $990.59 | 22.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 91 | $4,918 | $747.20 | 15.2% |
About Dr. Stanton Danielson, MD
Dr. Stanton Danielson, MD is a Family Medicine healthcare provider based in Altoona, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629038195.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stanton Danielson, MD has received a total of $419.54 in payments from pharmaceutical and medical device companies, with $29.64 received in 2023. These payments were reported across 39 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($419.54).
As a Medicare-enrolled provider, Danielson has provided services to 14,521 Medicare beneficiaries, totaling 27,132 services with total Medicare billing of $814,052. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Altoona, IA
- Active Since 03/27/2006
- Last Updated 08/15/2012
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1629038195
Products in Payments
- TROKENDI XR (Drug) $221.92
- LINZESS (Drug) $49.36
- VRAYLAR (Drug) $33.73
- QULIPTA (Drug) $29.64
- Tresiba (Drug) $15.72
- HETLIOZ (Drug) $14.71
- XIFAXAN (Drug) $14.35
- VIBERZI (Drug) $14.25
- Victoza (Drug) $12.24
- NAMZARIC (Drug) $9.03
- VIIBRYD (Drug) $4.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Altoona
David Lemchak, Do, DO
Family Medicine — Payments: $8,660
Family Medicine $8,660
Mr. Elias Rifkah, Md, MD
Family Medicine — Payments: $8,131
Family Medicine $8,131
Amanda Cattoi-Seifert, Md, MD
Family Medicine — Payments: $6,899
Family Medicine $6,899
Jeffrey Armstrong, Md, MD
Family Medicine — Payments: $2,402
Family Medicine $2,402
Dr. John Reinhardt, D.o, D.O
Family Medicine — Payments: $2,067
Family Medicine $2,067
Sarah Reinhardt, D.o, D.O
Family Medicine — Payments: $1,812
Family Medicine $1,812